Revolution Medicines reported daraxonrasib (RMC-6236) produced substantial objective responses in RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC), prompting plans toward a Phase 3 trial. In a first-line, treatment-naïve cohort the RAS(ON) tri-complex inhibitor produced an ORR around the high 40s percent with an 89% disease control rate and an encouraging tolerability profile. The data, drawn from cohorts described in company materials, compares favorably to historical chemotherapy benchmarks such as gemcitabine/nab‑paclitaxel and FOLFIRINOX. Grade ≥3 treatment-related adverse events were lower than historical chemotherapy rates, though dose modifications were common. Progression-free and overall survival remain immature. Revolution Medicines and investigators emphasize daraxonrasib’s potential as a chemotherapy-sparing option for the majority of PDAC driven by RAS mutations. The company is advancing toward the RASolute 303 pivotal program and continuing combination and monotherapy cohorts to refine patient selection and durability expectations.